SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA
630 patients with haematemesis and melaena were randomly allocated to treatment by a constant intravenous infusion of either somatostatin or an apparently identical placebo in a double-blind controlled trial. Rebleeding was less common in treated patients (70 episodes in 315 individuals compared wit...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1985-01, Vol.325 (8421), p.130-132 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 132 |
|---|---|
| container_issue | 8421 |
| container_start_page | 130 |
| container_title | The Lancet (British edition) |
| container_volume | 325 |
| creator | Somerville, K.W. Davies, J.G. Hawkey, C.J. Henry, D.A. Hine, K.R. Langman, M.J.S. |
| description | 630 patients with haematemesis and melaena were randomly allocated to treatment by a constant intravenous infusion of either somatostatin or an apparently identical placebo in a double-blind controlled trial. Rebleeding was less common in treated patients (70 episodes in 315 individuals compared with 89 episodes in 315 controls) but the difference was not significant. Operation rates were virtually identical (35 treated patients and 34 controls), while there were slightly more deaths in the treated group than in the controls (31 and 25, respectively). These results are in clear disagreement with those of other smaller series. Though it is not possible to be completely sure that treatment is not useful in some individuals, earlier claims of marked benefit seem unlikely to be justified. |
| doi_str_mv | 10.1016/S0140-6736(85)91903-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2156483940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673685919038</els_id><sourcerecordid>2156483940</sourcerecordid><originalsourceid>FETCH-LOGICAL-c279t-7f953b768c8a6179aa9df824618285a55affcbf884b2715f0c757a12de2305433</originalsourceid><addsrcrecordid>eNqFkN1LwzAUxYMoOKd_glDQB32oJmk-n6TMzg3WFmwF30KWJtAx15lsgv-93Qd7FS7ch_s753IOALcIPiGI2HMFEYEx4wl7EPRRIgmTWJyBASKcxJTwz3MwOCGX4CqEBYSQMEgHgFZlntZlVaf1tIj6qd-ztM6zoo7KcTRJs_6a5Vk1raK0eI3ybJZmRXoNLpxeBntz3EPwMc7q0SSelW_TUTqLDeZyE3MnaTLnTBihGeJSa9k4gQlDAguqKdXOmbkTgswxR9RBwynXCDcWJ5CSJBmCu4Pv2nffWxs2atFt_ap_qTCijIhEEthT9EAZ34XgrVNr335p_6sQVLuG1L4htYuvBFX7hpTodfdHdx2MXjqvV6YNJ7HEkmFOeuzlgNk-6U9rvQqmtStjm9Zbs1FN1_7z6A-5lXMD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2156483940</pqid></control><display><type>article</type><title>SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Somerville, K.W. ; Davies, J.G. ; Hawkey, C.J. ; Henry, D.A. ; Hine, K.R. ; Langman, M.J.S.</creator><creatorcontrib>Somerville, K.W. ; Davies, J.G. ; Hawkey, C.J. ; Henry, D.A. ; Hine, K.R. ; Langman, M.J.S.</creatorcontrib><description>630 patients with haematemesis and melaena were randomly allocated to treatment by a constant intravenous infusion of either somatostatin or an apparently identical placebo in a double-blind controlled trial. Rebleeding was less common in treated patients (70 episodes in 315 individuals compared with 89 episodes in 315 controls) but the difference was not significant. Operation rates were virtually identical (35 treated patients and 34 controls), while there were slightly more deaths in the treated group than in the controls (31 and 25, respectively). These results are in clear disagreement with those of other smaller series. Though it is not possible to be completely sure that treatment is not useful in some individuals, earlier claims of marked benefit seem unlikely to be justified.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(85)91903-8</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Biological and medical sciences ; Diabetes ; Digestive system ; Drug dosages ; Endoscopy ; Hemoglobin ; Hospitals ; Intravenous administration ; Intravenous infusion ; Medical sciences ; Patients ; Pharmacology. Drug treatments ; Somatostatin ; Transplants & implants ; Ulcers</subject><ispartof>The Lancet (British edition), 1985-01, Vol.325 (8421), p.130-132</ispartof><rights>1985</rights><rights>1985 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jan 19, 1985</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c279t-7f953b768c8a6179aa9df824618285a55affcbf884b2715f0c757a12de2305433</citedby><cites>FETCH-LOGICAL-c279t-7f953b768c8a6179aa9df824618285a55affcbf884b2715f0c757a12de2305433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673685919038$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9296274$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Somerville, K.W.</creatorcontrib><creatorcontrib>Davies, J.G.</creatorcontrib><creatorcontrib>Hawkey, C.J.</creatorcontrib><creatorcontrib>Henry, D.A.</creatorcontrib><creatorcontrib>Hine, K.R.</creatorcontrib><creatorcontrib>Langman, M.J.S.</creatorcontrib><title>SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA</title><title>The Lancet (British edition)</title><description>630 patients with haematemesis and melaena were randomly allocated to treatment by a constant intravenous infusion of either somatostatin or an apparently identical placebo in a double-blind controlled trial. Rebleeding was less common in treated patients (70 episodes in 315 individuals compared with 89 episodes in 315 controls) but the difference was not significant. Operation rates were virtually identical (35 treated patients and 34 controls), while there were slightly more deaths in the treated group than in the controls (31 and 25, respectively). These results are in clear disagreement with those of other smaller series. Though it is not possible to be completely sure that treatment is not useful in some individuals, earlier claims of marked benefit seem unlikely to be justified.</description><subject>Biological and medical sciences</subject><subject>Diabetes</subject><subject>Digestive system</subject><subject>Drug dosages</subject><subject>Endoscopy</subject><subject>Hemoglobin</subject><subject>Hospitals</subject><subject>Intravenous administration</subject><subject>Intravenous infusion</subject><subject>Medical sciences</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Somatostatin</subject><subject>Transplants & implants</subject><subject>Ulcers</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><recordid>eNqFkN1LwzAUxYMoOKd_glDQB32oJmk-n6TMzg3WFmwF30KWJtAx15lsgv-93Qd7FS7ch_s753IOALcIPiGI2HMFEYEx4wl7EPRRIgmTWJyBASKcxJTwz3MwOCGX4CqEBYSQMEgHgFZlntZlVaf1tIj6qd-ztM6zoo7KcTRJs_6a5Vk1raK0eI3ybJZmRXoNLpxeBntz3EPwMc7q0SSelW_TUTqLDeZyE3MnaTLnTBihGeJSa9k4gQlDAguqKdXOmbkTgswxR9RBwynXCDcWJ5CSJBmCu4Pv2nffWxs2atFt_ap_qTCijIhEEthT9EAZ34XgrVNr335p_6sQVLuG1L4htYuvBFX7hpTodfdHdx2MXjqvV6YNJ7HEkmFOeuzlgNk-6U9rvQqmtStjm9Zbs1FN1_7z6A-5lXMD</recordid><startdate>19850119</startdate><enddate>19850119</enddate><creator>Somerville, K.W.</creator><creator>Davies, J.G.</creator><creator>Hawkey, C.J.</creator><creator>Henry, D.A.</creator><creator>Hine, K.R.</creator><creator>Langman, M.J.S.</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>KB~</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>19850119</creationdate><title>SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA</title><author>Somerville, K.W. ; Davies, J.G. ; Hawkey, C.J. ; Henry, D.A. ; Hine, K.R. ; Langman, M.J.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c279t-7f953b768c8a6179aa9df824618285a55affcbf884b2715f0c757a12de2305433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Biological and medical sciences</topic><topic>Diabetes</topic><topic>Digestive system</topic><topic>Drug dosages</topic><topic>Endoscopy</topic><topic>Hemoglobin</topic><topic>Hospitals</topic><topic>Intravenous administration</topic><topic>Intravenous infusion</topic><topic>Medical sciences</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Somatostatin</topic><topic>Transplants & implants</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Somerville, K.W.</creatorcontrib><creatorcontrib>Davies, J.G.</creatorcontrib><creatorcontrib>Hawkey, C.J.</creatorcontrib><creatorcontrib>Henry, D.A.</creatorcontrib><creatorcontrib>Hine, K.R.</creatorcontrib><creatorcontrib>Langman, M.J.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Newsstand Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Somerville, K.W.</au><au>Davies, J.G.</au><au>Hawkey, C.J.</au><au>Henry, D.A.</au><au>Hine, K.R.</au><au>Langman, M.J.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA</atitle><jtitle>The Lancet (British edition)</jtitle><date>1985-01-19</date><risdate>1985</risdate><volume>325</volume><issue>8421</issue><spage>130</spage><epage>132</epage><pages>130-132</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>630 patients with haematemesis and melaena were randomly allocated to treatment by a constant intravenous infusion of either somatostatin or an apparently identical placebo in a double-blind controlled trial. Rebleeding was less common in treated patients (70 episodes in 315 individuals compared with 89 episodes in 315 controls) but the difference was not significant. Operation rates were virtually identical (35 treated patients and 34 controls), while there were slightly more deaths in the treated group than in the controls (31 and 25, respectively). These results are in clear disagreement with those of other smaller series. Though it is not possible to be completely sure that treatment is not useful in some individuals, earlier claims of marked benefit seem unlikely to be justified.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(85)91903-8</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1985-01, Vol.325 (8421), p.130-132 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2156483940 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Biological and medical sciences Diabetes Digestive system Drug dosages Endoscopy Hemoglobin Hospitals Intravenous administration Intravenous infusion Medical sciences Patients Pharmacology. Drug treatments Somatostatin Transplants & implants Ulcers |
| title | SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T14%3A47%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SOMATOSTATIN%20IN%20TREATMENT%20OF%20HAEMATEMESIS%20AND%20MELAENA&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Somerville,%20K.W.&rft.date=1985-01-19&rft.volume=325&rft.issue=8421&rft.spage=130&rft.epage=132&rft.pages=130-132&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(85)91903-8&rft_dat=%3Cproquest_cross%3E2156483940%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2156483940&rft_id=info:pmid/&rft_els_id=S0140673685919038&rfr_iscdi=true |